Payload Synthesis

Unlock the full potential of ADCs with potent, optimized payloads backed by cutting-edge medicinal chemistry.

We have experience in a wide variety of high potent compound synthesis which includes the derivatization of:

Tubulin Inhibitors
Topoisomerase 1 inhibitors
DNA Damaging agents

We provide structure-based payload optimization, focusing on potency, solubility, permeability, and plasma stability.

Our payload synthesis services include:

Potency (cellular and biochemical) optimization.
Solubility, permeability, and efflux optimization.
Plasma stability and scale-up.
HP-API manufacture.

Speak to our experts

Why choose Aurigene?

Specialized expertise in high-potency APIs, including tubulin inhibitors, topoisomerase I inhibitors, and DNA-damaging agents

Structure-based optimization for potency, permeability, solubility, and plasma stability

Capabilities from derivatization to HP-API manufacture under rigorous quality standards

Integrated services spanning discovery to scale-up for efficient ADC program acceleration

Over 20 years of proven expertise in designing and developing novel compounds for Oncology and other therapeutic areas, enabling deep scientific insight and innovation.

Dedicated CADD and AI/ML team with extensive experience in supporting ADC design and optimization, accelerating the path from concept to candidate.

Other Services

Monoclonal Antibody (mAb) Discovery Services

mRNA Synthesis by In vitro Transcription (IVT mRNA synthesis)

Viral Vectors Services

Virtual Tour

Hyderabad R and D Center

Bangalore R and D Center

Connect with our scientific experts for your drug discovery, development, and manufacturing needs

We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.

Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

I agree to receive updates from Aurigene

* I agree and accept the Privacy Policy and Terms of Use of this website.

Page name

page url

Learning Resources

Oligonucleotide as a novel class of therapeutic modality

Oligonucleotides as a therapeutic class is a revolutionary approach to discover new and important therapeutic agents for treating human diseases. RNA-based intervention at times works in cases where other modalities do not work. For example, it may help in treating inborn errors in metabolism, genetic disorders and rareOligonucleotide therapeutics is the use of c...

View All

HPAPI Molecule from Development to Market

The global Highly Potent Active Pharmaceutical Ingredients (HPAPI) market is expected to reach USD 26.84 Billion by 2023 from USD 17.72 Billion in 2018, at a CAGR 8.7%....

View All

Antibody Discovery (Tool Reagent)

View All

Systematic formulation design - shorten development cost & time

Project Challenge: Existing formulation (lower strength - 50 mg) was manufactured using direct compression process. This formulation posed poor powder flow and content uniformity issues during scale-up. Development of new strength 150 mg without any process issues was a challenge. Solution design: Preliminary pre-formulation, stress study and PSD impact assessmen...

View All

An efficient and convenient protocol for the synthesis of tetracyclic isoindolo[1,2-a]quinazoline derivatives

2016

A convenient and one-pot synthesis of tetracyclic isoindolo [1,2-a]quinazoline derivatives via Lewis acid mediated sequential C–N bond formation reactions is reported. This protocol provides a simple and rapid strategy for the synthesis of 12-benzylidene-10,12-dihydroisoindolo[1,2-b]quinazoline derivatives. However, a variety of tetracyclo indole fused quinazol...

Development and assessment of a Bcs class II - SGLT2 (Sodium Glucose Cotransporter 2) inhibitor drug in the form of solid lipid Nanoparticles by selecting different lipids, co-surfactants, and manufacturing techniques

Drug Delivery System (DDS) has been used successfully in the past few decades to cure illnesses and enhance health because of its improved systemic circulation and ability to regulate the drug's pharmacological action. As pharmacology and pharmacokinetics advanced, the idea of controlled release emerged, demonstrating the significance of drug release in assessing...
Read More
Development of novel paullone-based PROTACs as anticancer agents

Proteolysis-targeting chimera (PROTACs) represents a promising modality that has gained significant attention for cancer treatment. Using PROTAC technology, we synthesized novel structurally modified paullone-based PROTACs using Cereblon (CRBN) and Von Hippel–Lindau (VHL) E3 ligands....
Read More
Development and verification of RP-HPLC method for the quantitative determination of Decitabine in tablet dosage formulation

Decitabine is an anti-cancer chemotherapy drug. This article describes method development and method verification of Assay of Decitabine in tablet formulation. A new, precise, rapid, accurate RP-HPLC method has been developed for the estimation of Decitabine in pharmaceutical tablets dosage form. After optimization the good chromatographic separation was achieved...
Read More

View All

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

Proceed Back

Payload Synthesis